

203. VAISEY, E. B.: Non-enzymic reduction of trimethylamine oxide to trimethylamine, dimethylamine, and formaldehyde. *Can. J. Biochem. Physiol.* 34: 1085-1090, 1956.

204. WATANABE, M. AND ISHIDATE, M.: Metabolism of 4-dimethylaminoazobenzene and related compounds. V. Quantitative analysis of biliary and urinary metabolites of 4-dimethylaminoazobenzene in rat. *Chem. Pharm. Bull. (Japan)* 15: 1461-1469, 1967.

205. WEDER, H. J. AND BICKEL, M. H.: Separation and determination of imipramine and its metabolites from biological samples by gas-liquid chromatography. *J. Chromatogr.* 37: 181-189, 1968.

206. WENKERT, E.: The role of oxidation in the biogenesis of alkaloids. *Experientia* 10: 346-350, 1954.

207. WHITE, E. C. AND HILL, J. H.: Studies on antibacterial products formed by molds. I. Aspergillic acid, a product of a strain of *Aspergillus flavus*. *J. Bacteriol.* 45: 433-442, 1943.

208. WOLF, F. J., PFISTER, K., WILSON, R. M. AND ROBINSON, C. A.: Benzotriazines. I. A new series of compounds having antimalarial activity. *J. Amer. Chem. Soc.* 76: 3551-3553, 1954.

209. WOO, J. T. C., GAFF, G. A. AND FENNESSY, M. R.: A note on the effects of 2,4-diamino-5-phenylthiasole and 1,2,3,4-tetrahydro-9-aminoacridine on morphine metabolism. *J. Pharm. Pharmacol.* 20: 763-767, 1968.

210. ZIEGLER, D. M., MACHINIST, J. M. AND DEHNER, E. W.: Function of the microsomal CO-binding pigment in oxidative N-dealkylation. *Fed. Proc.* 26: 729, 1967.

211. ZIEGLER, D. M. AND PETTIT, F.: Properties of a liver microsomal N-oxide demethylase. *Fed. Proc.* 23: 325, 1964.

212. ZIEGLER, D. M. AND PETTIT, F. H.: Formation of an intermediate N-oxide in the oxidative demethylation of N,N-dimethylaniline catalysed by liver microsomes. *Biochem. Biophys. Res. Commun.* 15: 188-193, 1964.

213. ZIEGLER, D. M. AND PETTIT, F. H.: Microsomal oxidases. I. The isolation and dialkylarylamine oxygenase activity of pork liver microsomes. *Biochemistry* 5: 2932-2938, 1966.

214. ZIEGLER, D. M., PETTIT, F. H. AND ORME-JOHNSON, W. H.: Properties of an alkylarylamine oxygenase concentrated from pork liver microsomes. *Fed. Proc.* 24: 604, 1965.

215. ZINS, G. R., EMMERT, D. E. AND WALK, R. A.: The metabolism of diallylmelamin-N-oxide. *Pharmacologist* 6: 245, 1964.

**Statement of Ownership, Management and Circulation required by the Act of October 23, 1962; Section 4369, Title 39, United States Code.**

1. *Date of Filing:* October 1, 1969.
2. *Title of Publication:* Pharmacological Reviews.
3. *Frequency of Issue:* Quarterly.
4. *Location of known Office of Publication:* 428 E. Preston St., Baltimore, Md. 21202.
5. *Location of the Headquarters or General Business Offices of Publisher:* 428 E. Preston St., Baltimore, Md. 21202.
6. *Publisher:* The Williams & Wilkins Company, 428 E. Preston St., Baltimore, Md. 21202.  
*Editor:* Dr. George H. Acheson, University of Cincinnati, Cincinnati, Ohio 45219.
7. *Owners:* (If owned by a corporation, its name and address must be stated and also immediately thereunder the names and addresses of stockholders owning or holding 1 percent or more of total amount of stock. If not owned by a corporation, the names and addresses of the individual owners must be given. If owned by a partnership or other unincorporated firm, its name and address, as well as that of each individual, must be given.) American Society for Pharmacology and Experimental Therapeutics, Inc., 9650 Rockville Pike, Bethesda, Md. 20014. No stockholders.
8. *Known bondholders, mortgagees and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages or other securities are:* None.
9. Paragraphs 7 and 8 include, in cases where the stockholder or security holder appears upon the books of the company as trustee or in any other fiduciary relation, the name of the person or corporation for whom such trustee is acting, also the state-

ments in the two paragraphs show the affiant's full knowledge and belief as to the circumstances and conditions under which stockholders and security holders who do not appear upon the books of the company as trustees, hold stock and securities in a capacity other than that of a bona fide owner. Names and addresses of individuals who are stockholders of a corporation which itself is a stockholder or holder of bonds, mortgages or other securities of the publishing corporation have been included in Paragraphs 7 and 8 when the interests of such individuals are equivalent to 1 percent or more of the total amount of the stock or securities of the publishing corporation.

	(a)*	(b)†
10. A. Total No. Copies Printed (Net Press Run).....	3750	3850
B. Paid Circulation		
1. To term subscribers by mail, carrier delivery or by other means).....	3330	3019
2. Sales through agents, news dealers or otherwise.....	—	—
C. Free Distribution (including samples), by mail, carrier delivery or by other means.....	41	39
D. Total No. of copies distributed.....	3371	3058

\* Average no. of copies for each issue during preceding 12 months.

† Single issue nearest to filing date.

I certify that the statements made by me above are correct and complete. (Signed) Mary G. MacIsaac, Publisher.

## INDEX

### PHARMACOLOGICAL Reviews

Volume 21

1969

- Amines, sympathomimetic, action on skeletal muscle, 27
- Anemia, hemolytic, drug-induced, 73
- Antibiotics, mammalian protein synthesis inhibition, 213
- Armentrout, Steven A. See Beard, Armentrout, and Weisberger, 213
- Ashmore, James. See Mayhew, Wright, and Ashmore, 183
- Autonomic innervation of visceral and cardiovascular systems in vertebrates, evolution of, 248
- Beard, N. Shelly, Jr., Steven A. Armentrout, and Austin S. Weisberger. Inhibition of mammalian protein synthesis by antibiotics, 213
- Beutler, Ernest. Drug-induced hemolytic anemia, 73
- Bickel, M. H. The pharmacology and biochemistry of N-oxides, 325
- Biochemistry of N-oxides, 325
- Bowman, W. C. and M. W. Nott. Actions of sympathomimetic amines and their antagonists on skeletal muscle, 27
- Brendel, K. See Bressler, Corredor, and Brendel, 105
- Bressler, R., C. Corredor, and K. Brendel. Hypoglycin and hypoglycin-like compounds, 105
- Burnstock, G. Evolution of the autonomic innervation of visceral and cardiovascular systems in vertebrates, 248
- Cardiovascular system in vertebrates, evolution of autonomic innervation, 248
- Corredor, C. See Bressler, Corredor, and Brendel, 105
- Drug-induced hemolytic anemia, 73
- Ehrenpreis, Seymour, Jerome H. Fleisch, and Thomas W. Mittag. Approaches to the molecular nature of pharmacological receptors, 131
- Fairhurst, Alan S. See Jenden and Fairhurst, 1
- Fleisch, Jerome H. See Ehrenpreis, Fleisch, and Mittag, 131
- Hemolytic anemia, drug-induced, 73
- Hypoglycin and hypoglycin-like compounds, 105
- Insulin secretion, regulation of, 183
- Jenden, Donald J., and Alan S. Fairhurst. The pharmacology of ryanodine, 1
- Mammalian protein synthesis, inhibition by antibiotics, 213
- Mayhew, Dale A., Peter H. Wright, and James Ashmore. Regulation of insulin secretion, 183
- Mittag, Thomas W. See Ehrenpreis, Fleisch, and Mittag, 131
- Molecular nature of pharmacological receptors, approaches to, 131
- Muscle, skeletal, actions of sympathomimetic amines and their antagonists, 27
- Nott, M. W. See Bowman and Nott, 27
- N-Oxides, pharmacology and biochemistry, 325
- Pharmacological receptors, approaches to molecular nature of, 131
- Pharmacology of N-oxides, 325
- Pharmacology of ryanodine, 1
- Protein synthesis, mammalian, inhibition by antibiotics, 213
- Receptors, pharmacological, approaches to molecular nature of, 131
- Ryanodine, pharmacology of, 1
- Skeletal muscle, actions of sympathomimetic amines and their antagonists, 27

- Sympathomimetic amines and antagonists, actions on skeletal muscle, 27
- Vertebrates, evolution of autonomic innervation of visceral and cardiovascular systems, 248
- Visceral system in vertebrates, evolution of autonomic innervation, 248
- Weisberger, Austin S. See Beard, Armentrout, and Weisberger, 213
- Wright, Peter H. See Mayhew, Wright, and Ashmore, 183

BRONX MUNICIPAL HOSPITAL CENTER  
161st Street  
Bronx, N. Y.

7.2  
2367-26-1